$19.45
-0.026%Healthpeak Properties, Inc. is a fully integrated real estate investment trust (REIT) and S&P 500 company. Healthpeak owns, operates, and develops high-quality real estate for healthcare discovery and delivery.
Wall Street analysts project that DOC stock may see slight declines over the coming 12 months. The consensus 1-year price target stands at 18.75, with estimates ranging from a low of 17.00 to a high of 21.00.
The consensus 1-year price target stands at 18.75, with estimates ranging from a low of 17.00 to a high of 21.00.
Fair value territory. Stock trading near consensus target suggests limited near-term catalysts. Focus on fundamental developments.
Good consensus alignment. Moderate target spread reflects general agreement on value drivers with some variance in assumptions.
Unfavorable risk-reward. Downside risk exceeds upside potential. Consider defensive positioning or alternative opportunities.
Neutral sentiment. Fair value pricing with moderate agreement suggests wait-and-see approach or catalyst-driven opportunity.
Efficient pricing: Stock trading at fair value with strong consensus suggests market has priced in expectations. Look for fundamental inflection points or new catalysts to drive meaningful moves.
Declining expectations indicate headwindsโinvestigate whether temporary or structural issues.
Moderate coverageโsufficient for guidance but may lack depth of large-cap analysis.
Narrow estimate range signals strong analyst consensus and predictable business outlook.
Mixed signalsโsome positive indicators offset by concerns about growth or uncertainty.
Strong growth expectations signal robust business momentum and market opportunity expansion.
Moderate coverageโsufficient for guidance but may lack depth of large-cap analysis.
Narrow estimate range signals strong analyst consensus and predictable business outlook.
Positive analyst consensus with strong growth expectations and forecast confidence.
Compelling growth story with analyst consensus: Strong projected growth combined with narrow estimate spread suggests high-conviction opportunity.
Strong growth expectations signal robust business momentum and market opportunity expansion.
Limited coverage may indicate reduced institutional interest or information availability.
Narrow estimate range signals strong analyst consensus and predictable business outlook.
Generally favorable outlook with reasonable growth prospects and analyst support.
Compelling growth story with analyst consensus: Strong projected growth combined with narrow estimate spread suggests high-conviction opportunity.
Strong growth expectations signal robust business momentum and market opportunity expansion.
Moderate coverageโsufficient for guidance but may lack depth of large-cap analysis.
Narrow estimate range signals strong analyst consensus and predictable business outlook.
Positive analyst consensus with strong growth expectations and forecast confidence.
Compelling growth story with analyst consensus: Strong projected growth combined with narrow estimate spread suggests high-conviction opportunity.
Moderate growth expected, typical for mature businesses with stable market positions.
Moderate coverageโsufficient for guidance but may lack depth of large-cap analysis.
Narrow estimate range signals strong analyst consensus and predictable business outlook.
Generally favorable outlook with reasonable growth prospects and analyst support.
Strong growth expectations signal robust business momentum and market opportunity expansion.
Moderate coverageโsufficient for guidance but may lack depth of large-cap analysis.
Narrow estimate range signals strong analyst consensus and predictable business outlook.
Positive analyst consensus with strong growth expectations and forecast confidence.
Compelling growth story with analyst consensus: Strong projected growth combined with narrow estimate spread suggests high-conviction opportunity.
During the last 12 months, insiders have purchased $150K and sold $214K worth of DOC shares, resulting in $64K of net selling activity.
0
0.00
11.0K
213.74K
-214K
-$214K
0
0.00
0
0.00
+0
+$0
0
0.00
0
0.00
+0
+$0
8.7K
149.78K
0
0.00
+150K
+$150K
Brinker Scott M
Director, Officer: President And Ceo
$125K
Thomas John T
Director
$25K
Bohn Scott R
Officer: Cdo And Head Of Lab
$214K
Slightly bearish with $64K net selling. Selling modestly exceeds buying, which could be routine diversification rather than concern.
Moderately negative ratio. Selling is roughly double the buying, which may be routine or signal caution.
Heavy recent selling activity. Recent insider sales notably exceed purchasesโmay warrant investigation into company developments.
2 insider buyers vs. 1 sellers. More insiders buying than selling indicates positive sentiment.
Continue your DOC research with focused valuation guides.
Snapshot
Start with context, operating signals, and key market metrics.
Value Model
Stress test fair value across bear, base, and bull assumptions.
Statements
Validate revenue quality, margins, and balance sheet durability.
Earnings Call
Read management commentary and compare it with reported outcomes.
Dividends
Check payout sustainability and long-term distribution behavior.
Analyst Expectations
Review consensus spread and where estimate risk is concentrated.